Loading this company
Guardant Health, Inc.
GHPrices in USD
TickerWorth ScoreF39/100
What we think
We do not publish a fair value for this company. The grade still applies.
Price
$158.60USD down −$7.28 (−4.39%)
Close of · Prices are delayed.
Showing the last price we hold for this listing, recorded 2026-10-19 15:51 UTC (5 hours ago).
Why did it move today?
Nothing we can cite explains today’s move for this company.
We do not put a fair value on this one
Our cash-flow model doesn't produce a meaningful value for this business — its projected free cash flow is so far from supporting the current price that the result is effectively zero, which tells you about the limits of the model on a fast-growing or loss-making company, not about what the business is worth. Here is what we can show instead.
Is it a good business?
- Growth100 out of 100
- Financial health75 out of 100
- Past performance50 out of 100
Bull, base, bear
Our forward range over 12 months is part of Pro. See plans
The street
Analysts’ mean target
$201.64 across 25 analysts
The high and low of the analyst range is part of Pro. See plans
What does it do?
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It operates in the Diagnostics & Research industry (Healthcare sector), headquartered in United States. The company employs roughly 2,490 people.
Key stats
52-week range$65.96–$191.05
- Open
- $160.65
- Day high
- $163.91
- Day low
- $155.31
- Previous close
- $158.60
- Volume
- 529,541 · 0.27× avg
- Average volume
- 1,941,573
- Market cap
- $21,186,891,776.00
- P/E (TTM)
- —
- Earnings per share
- −$3.50
- Beta
- 1.58
Prices are delayed. The feed does not say when these figures were taken.
What’s the latest?
- Reported quarterly or annual results
- Reported shareholder vote results
- Reported quarterly or annual results
- Changed leadership or its board
- Reported quarterly or annual results
- Reported quarterly or annual results
- Signed a material agreement
Top news
No recent headlines we can cite for this company.
Insider trades
The 90-day buying-and-selling read is part of Pro. See plans
- Azar Alex M IIOpen-market sale · $11,032.41
- Azar Alex M IIOption exercise ·
Not investment advice. TickerWorth Score is a model output.